化疗结合美洛昔康治疗晚期胰腺癌疗效分析

Efficacy of Chemotherapy Combined with Meloxicam in the Treatment of Advanced Pancreatic Cancer

目的探讨全身化疗加或不加美洛昔康对胰腺癌的疗效及毒性变化。方法将90例胰腺癌患者随机分为治疗组和对照组,分别接受GP方案(吉西他滨,顺铂)加美洛昔康或单纯GP方案化疗。结果治疗组(GP+Meloxicam):总有效率(CR+PR)为33.3%(15/45),对照组(GP regimen):为22.2%(10/45)。中位生存期分别为9.4个月及7.6个月,无进展生存期分别为7.2个月及5.1个月,毒副作用未见增加。结论全身化疗同时,应用美洛昔康治疗晚期胰腺癌疗效有所提高,且毒性未见增加。

Objective To investigate the efficacy and toxicity of combination chemotherapy with or without meloxi- cam in treatment of advanced pancreatic cancer. Methods Ninety patients with advanced pancreatic cancer were randomly divided into treatment group and control group, and were respectively treated with GP regimen （gemcit- abine, eisplatin） plus meloxieam or simple GP regimen chemotherapy. Results The total effective rate （CR ＋ PR） of treatment group （ GP ＋ Meloxicam） was 33.3% （ 15/45）, and the control group （ GP regimen） was 22.2% （10/45）. The median survival time was 9.4 months and 7.6months, progression - free survival was 7.2 months and 5.1 months, the side effects did not increase. Conclusion Chemotherapy with Meloxicam can ira- prove the therapeutic effect of advanced pancreatic cancer without increase of toxicity.